Is Surgery Partners (SGRY) Fully Valued On Reaffirmed 2026 Guidance?
Surgery Partners (SGRY) recently reaffirmed its 2026 earnings guidance, telling investors to expect revenues between US$3.35b and US$3.45b. This keeps attention on how the company balances this outlook with ongoing operational challenges.
See our latest analysis for Surgery Partners.
Despite reaffirmed guidance, Surgery Partners’ recent trading tells a mixed story. The stock has fallen about 7% on a 30 day share price return basis but is still up nearly 8% over 90 days. The 1 year total shareholder return is down about 28%, pointing to fragile momentum as investors reassess growth and balance sheet risks.
If this kind of volatility has you comparing opportunities in healthcare, it can help to scan a wider set of companies using our screener for 41 healthcare AI stocks
So with Surgery Partners reaffirming its revenue outlook yet carrying weak recent returns and a rich 33.3x forward P/E, does the current pullback finally tilt the risk reward toward buyers, or does the valuation still look demanding?
Most Popular Narrative: 14.2% Undervalued
The most followed narrative currently places Surgery Partners' fair value at $17.95, above the last close at $15.40. This puts a spotlight on its long term earnings potential and margin repair story.
Recent and proposed regulatory changes (such as CMS expanding the ASC covered procedure list, phasing out the inpatient-only list, and supporting site-of-care neutrality) are expected to further expand the company's addressable market, enabling more complex and higher-reimbursement procedures to move into their centers, which should positively affect revenue and earnings growth.
Want to see what is sitting behind that fair value for Surgery Partners? The narrative focuses on volume growth, rising margins, and a richer earnings base. Curious which assumptions really move the model? The full breakdown spells out the revenue path, profit swing, and valuation multiple that tie it all together.
Result: Fair Value of $17.95 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Surgery Partners narrative still leans on fragile pillars, with higher interest costs and slower deal activity both capable of undercutting the 2026 recovery story.
Find out about the key risks to this Surgery Partners narrative.
Next Steps
Given the mixed tone around Surgery Partners, it makes sense to move quickly and check the facts yourself so you are not relying solely on sentiment. To see what others view as the main bright spots in the story, review the 3 key rewards
Looking for more investment ideas beyond Surgery Partners?
If you want a clearer view of where to put fresh capital next, use the Simply Wall Street Screener to quickly spot stocks that better match your goals.
- Target potential long term compounders by checking out 55 high quality undervalued stocks that currently trade below their estimated worth.
- Prioritise resilience by focusing on companies in the 81 resilient stocks with low risk scores that show lower overall risk scores.
- Get ahead of the crowd by scanning the screener containing 19 high quality undiscovered gems before they appear on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com